Valentina Gambardella
Valencia, VC, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 90 publications
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.
Journal: Journal for immunotherapy of cancer
Published: May 19, 2026
Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 22, 2026
Finding More in Less: Precision Medicine for Pancreatic Cancer Using Residual Cytology Samples.
Journal: Cytopathology : official journal of the British Society for Clinical Cytology
Published: August 18, 2025
Clinical performance of tumor-informed versus tumor-agnostic ctDNA assays for colorectal cancer recurrence: A systematic review and diagnostic accuracy meta-analysis.
Journal: Cancer treatment reviews
Published: August 06, 2025
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 24, 2025
Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 22, 2025
Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterations.
Journal: ESMO open
Published: May 20, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 20, 2025
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 19, 2025
Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors.
Journal: Future oncology (London, England)
Published: January 16, 2025
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors.
Journal: Cancer research communications
Published: January 02, 2025
Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).
Journal: ESMO open
Published: December 18, 2024
Last Updated: 09/26/2026